KNTPF
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.25 | $26M | -$100M |
| 2025 Q2 | -0.03 | $818,570 | -$70M |
| 2024 Q4 | -0.03 | $3M | -$89M |
| 2024 Q2 | -0.02 | $3M | -$111M |
| 2023 Q4 | -1.98 | $0 | -$175,978 |
| 2023 Q2 | -0.50 | $0 | -$214,326 |
| 2022 Q4 | -1.13 | $0 | -$269,543 |
| 2022 Q2 | -1.42 | $0 | -$719,187 |